Takeda and PvP Biologics Announce Development Agreement around Novel Therapeutic for Celiac Disease

OSAKA, Japan & SAN DIEGO & SEATTLE–(BUSINESS WIRE)– Takeda Pharmaceutical Company Limited (“Takeda”) (TOKYO:4502) and PvP Biologics, Inc. (“PvP”) today announced a global agreement for the development of KumaMax, a novel enzyme designed to break …
( read original story …)


Related Post

SanBio: Notice Regarding an Equity and Business Al...
views 36
TOKYO--(BUSINESS WIRE)--SanBio Co., Ltd. (represen...
Japan’s Abe rolls out red carpet for Trump
views 190
TOKYO -- Prime Minister Shinzo Abe is lavishing U....
This Story is About…
views 204
The Rangers ran the attached ad on Sunday morning ...
Japan stocks higher at close of trade; Nikkei 225 ...
views 210
Investing.com – Japan stocks were higher after the...
The Japanese yen is climbing as global markets go ...
views 258
The Japanese yen is climbing. The currency was up ...
Apple supplier Japan Display seeks $893 million to...
views 186
(Reuters) - Liquid crystal display panels manufact...
Tokyo Olympics near $25 billion US — may go higher...
views 21
The price tag keeps soaring for the 2020 Tokyo Oly...
Japan secure 2018 FIFA World Cup berth with Austra...
views 176
Japan had never beaten Australia in a World Cup qu...
Wary of North Korea, Japan mulls additional milita...
views 198
North Korea’s recent test firing of a missile over...
Nagoya doctor’s treatment research deflates overbl...
views 169
Medical information on how to treat patients bitte...